Taysha Gene Therapies (NASDAQ:TSHA) and Evoke Pharma (NASDAQ:EVOK) Head-To-Head Comparison

Evoke Pharma (NASDAQ:EVOK) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Volatility & Risk

Evoke Pharma has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Profitability

This table compares Evoke Pharma and Taysha Gene Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evoke Pharma	-42.07%	-99.48%	-33.58%
Taysha Gene Therapies	-1,144.97%	-67.26%	-42.14%

Analyst Ratings

This is a breakdown of current ratings for Evoke Pharma and Taysha Gene Therapies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evoke Pharma	1	1	0	0	1.50
Taysha Gene Therapies	1	0	10	1	2.92

Taysha Gene Therapies has a consensus price target of $9.70, indicating a potential upside of 122.48%. Given Taysha Gene Therapies’ stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Evoke Pharma.

Institutional & Insider Ownership

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 2.3% of Evoke Pharma shares are owned by company insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Evoke Pharma and Taysha Gene Therapies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evoke Pharma	$10.25 million	1.63	-$5.35 million	($2.56)	-4.17
Taysha Gene Therapies	$8.33 million	143.37	-$89.30 million	($0.33)	-13.21

Evoke Pharma has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Evoke Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Taysha Gene Therapies beats Evoke Pharma on 10 of the 15 factors compared between the two stocks.

About Evoke Pharma

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.